| Literature DB >> 30008643 |
Anna Bednarek1, Anna Bodajko-Grochowska2, Małgorzata Bartkowiak-Emeryk3, Robert Klepacz4, Janusz Ciółkowski5, Danuta Zarzycka1, Andrzej Emeryk2.
Abstract
INTRODUCTION: Asthma control is an important measure of disease stabilization, which is linked to the treatment and lifestyle recommendations. AIM: To assess the impact of selected factors on asthma control in adolescents, as assessed using the Asthma Control Test (ACT™).Entities:
Keywords: Asthma Control Test; adolescents; asthma; asthma control
Year: 2018 PMID: 30008643 PMCID: PMC6041703 DOI: 10.5114/ada.2018.76221
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.837
Figure 1Study group selection process
Asthma patients’ characteristics
| Parameter | Result |
|---|---|
| Age (min.–max.) [years] | 12–19 |
| 12–15, | 57 (57) |
| > 15–19, | 43 (43) |
| Gender, | |
| Male | 76 (76) |
| Female | 24 (24) |
| Residence, | |
| Urban | 34 (34) |
| Rural | 66 (66) |
| Family history of allergies, | |
| Yes | 65 (65) |
| No | 35 (35) |
| Asthma phenotype, | |
| IgE-dependent | 70 (70) |
| Non-IgE-dependent | 30 (30) |
| Concurrent allergies, | |
| Allergic rhinitis | 58 (58) |
| Atopic dermatitis | 17 (17) |
| Asthma treatment, | |
| Inhaled GCs | 73 (73) |
| SABAs | 100 (100) |
| Inhaled GCs + LABAs | 27 (27) |
Overall ACT result for the asthma patients
| Score: asthma control | Visit | Statistical parameters | ||
|---|---|---|---|---|
| V1 | V2 | V3 | ||
| 25 points | 53 (53%) | 54 (54%) | 56 (56%) | |
| 20–24 points | 37 (37%) | 39 (39%) | 40 (40%) | |
| < 20 points | 10 (10%) | 7 (7%) | 4 (4%) | |
| Mean score ± SD | 22.73 ±3.33 | 23.18 ±2.96 | 23.42 ±2.52 | |
The value of FEV1/FCV% ratio on subsequent visits
| Visit | Min. | Max. | Mean | SD | Median | 25% | 75% | ||
|---|---|---|---|---|---|---|---|---|---|
| V1 | 100 | 78.07 | 80.18 | 78.47 | 0.83 | 78.07 | 78.07 | 78.07 | < 0.001 |
| V2 | 100 | 78.07 | 82.29 | 79.97 | 1.67 | 80.18 | 78.07 | 82.29 | |
| V3 | 100 | 77.02 | 84.40 | 79.42 | 2.85 | 78.07 | 77.02 | 80.18 |
Selected demographic characteristics (age, sex, residence) and asthma control as assessed using the ACT
| Sex | ACT score (points) | Boys | Girls | Statistical parameters |
|---|---|---|---|---|
| V1 | 25 | 40 (52.63) | 13 (54.17) | χ2 = 22.32 |
| 20–24 | 34 (44.74) | 3 (12.5) | ||
| < 20 | 2 (2.63) | 8 (33.33) | ||
| V2 | 25 | 40 (52.63) | 14 (58.33) | χ2 = 11.42 |
| 20–24 | 34 (44.74) | 5 (20.83) | ||
| < 20 | 2 (2.63) | 5 (20.83) | ||
| V3 | 25 | 40 (52.63) | 16 (66.67) | χ2 = 3.90 |
| 20–24 | 34 (44.74) | 6 (25) | ||
| < 20 | 2 (2.63) | 2 (8.33) | ||
| V1 | 25 | 33 (57.89) | 20 (46.51) | χ2 = 1.28 |
| 20–24 | 19 (33.33) | 18 (41.86) | ||
| < 20 | 5 (8.77) | 5 (11.63) | ||
| V2 | 25 | 34 (59.65) | 20 (46.51) | χ2 = 3.25 |
| 20–24 | 18 (31.58) | 21 (48.84) | ||
| < 20 | 5 (8.77) | 2 (4.65) | ||
| V3 | 25 | 36 (63.16) | 20 (46.51) | χ2 = 2.77 |
| 20–24 | 19 (33.33) | 21 (48.84) | ||
| < 20 | 2 (3.51) | 2 (4.65) | ||
| V1 | 25 | 33 (50.00) | 20 (58.82) | χ2 = 9.86 |
| 20–24 | 30 (45.45) | 7 (20.59) | ||
| < 20 | 3 (4.55) | 7 (20.59) | ||
| V2 | 25 | 33 (50.00) | 21 (61.76) | χ2 = 4.34 |
| 20–24 | 30 (45.45) | 9 (26.47) | ||
| < 20 | 3 (4.55) | 4 (11.76) | ||
| V3 | 25 | 33 (50.00) | 23 (67.65) | χ2 = 2.84 |
| 20–24 | 30 (45.45) | 10 (29.41) | ||
| < 20 | 3 (4.55) | 1 (2.94) |
Figure 2Medical considerations (A – treatment methods, B – allergen immunotherapy, C – concurrent allergic rhinitis and atopic dermatitis, D – asthma phenotype, E – family history of atopy) and asthma control assessed using the ACT